{"id":"NCT01737697","sponsor":"ZS Pharma, Inc.","briefTitle":"Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia","officialTitle":"Multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study of Safety and Efficacy of Microporous, Fractionated, Protonated Zirconium Silicate in Mild to Moderate Hyperkalemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-30","primaryCompletion":"2013-10-31","completion":"2013-11-30","firstPosted":"2012-11-29","resultsPosted":"2018-10-12","lastUpdate":"2018-10-12"},"enrollment":754,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Hyperkalemia"],"interventions":[{"type":"DRUG","name":"Zirconium silicate (acute phase)","otherNames":["ZS"]},{"type":"DRUG","name":"Zirconium silicate (subacute phase)","otherNames":["ZS"]},{"type":"DRUG","name":"Placebo (acute phase)","otherNames":["Silicified microcrystalline cellulose"]},{"type":"DRUG","name":"Placebo ( subacute phase)","otherNames":["Silicified microcrystalline cellulose"]}],"arms":[{"label":"Zirconium silicate (acute phase)","type":"EXPERIMENTAL"},{"label":"Placebo (acute phase)","type":"PLACEBO_COMPARATOR"},{"label":"Zirconium silicate (subacute phase)","type":"EXPERIMENTAL"},{"label":"Placebo (subacute phase)","type":"PLACEBO_COMPARATOR"}],"summary":"Acute Phase: It is hypothesized that ZS (zirconium silicate) is more effective than placebo control (alternative hypothesis) in lowering S-K levels in subjects with S-K between 5.0 - 6.5 mmol/l versus no difference between ZS and placebo control (null hypothesis).\n\nSubacute Phase (randomized withdrawal): It is hypothesized that ZS once daily is more effective than placebo control (alternative hypotheses) in maintaining normokalemic levels (3.5 - 4.9 mmol/l) among subjects completing the Acute Phase versus no difference between each ZS dose and respective placebo controls (null hypotheses).","primaryOutcome":{"measure":"Exponential Rate of Change in Serum Potassium (S-K) Levels During the Initial 48 Hours of Study Drug Treatment.","timeFrame":"Through 48 hours acute phase","effectByArm":[{"arm":"Acute Phase: Placebo TID","deltaMin":-0.00128,"sd":0.000243},{"arm":"Acute Phase: Sodium Zirconium Cyclosilicate (ZS) 1.25 g TID","deltaMin":-0.00187,"sd":0.00025},{"arm":"Acute Phase: ZS 2.5 g TID","deltaMin":-0.00205,"sd":0.000263},{"arm":"Acute Phase: ZS 5 g TID","deltaMin":-0.0028,"sd":0.00025},{"arm":"Acute Phase: ZS 10 g TID","deltaMin":-0.00382,"sd":0.000258}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":44,"countries":["United States","Australia"]},"refs":{"pmids":["32588430","31791288","29728199","25415807"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":158},"commonTop":["Urinary tract infection","Diarrhoea","Constipation","Nausea","Oedema peripheral"]}}